Francis Kim, MD
Cardiovascular Disease · New Hyde Park, NYNPI 1669783759
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,122 of the $12,881 with a category attached, or 70.8%. 17 manufacturers reported payments, led by Edwards Lifesciences at 36.0% of the total. Reporting peaked in 2023 at $4,158 and has fallen 73.8% since, to $1,090 in 2025.
Across 247 payments — averaging $52.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$5K
- Medtronic$3K
- Boston Scientific$2K
- Abiomed$1K
- Abbott$947
- Cardiovascular Systems Inc.$348
- plus $872 from 11 others
What the payments were for
- Travel & lodging$3,74129%
- Food & beverage$9,12271%
- Entertainment$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 70 | $4,632 |
| Medtronic(2 entities) | 30 | $3,274 |
| Boston Scientific | 11 | $1,532 |
| Abiomed | 45 | $1,276 |
| Abbott | 21 | $947 |
| Cardiovascular Systems Inc. | 6 | $348 |
| Johnson & Johnson | 42 | $316 |
| Shockwave Medical, Inc | 4 | $185 |
| Cardiva Medical, Inc. | 5 | $120 |
| Opsens Inc. | 4 | $101 |
| Penumbra, Inc. | 2 | $31 |
| Amgen | 2 | $30 |
| Terumo Medical Corporation | 1 | $26 |
| Stryker | 1 | $19 |
| Pfizer | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Resolute$1,555
- CoreValve Evolut$895
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$592
- NAVITOR$443
- Impella$356
- SAPIEN 3 Ultra RESILIA$343
- Coronary Orbital Atherectomy System$131
- CARDIOMEMS$129
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$127
- COREVALVE EVOLUT R$127
- Diamondback Peripheral$118
- Diamondback Coronary$118
- CROSSBOSS$115
How this compares
$12,881 in reported general payments places this provider in the 85th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 105 | $137,923 |
| XareltoRivaroxaban | 41 | $42,303 |
| Repatha SureclickEvolocumab | 24 | $38,558 |
| EntrestoSacubitril/Valsartan | 18 | $34,280 |
| BrilintaTicagrelor | 21 | $23,615 |
| LivaloPitavastatin Calcium | 13 | $10,481 |
| Atorvastatin Calcium | 293 | $4,485 |
| Metoprolol Succinate | 221 | $3,705 |
| Rosuvastatin Calcium | 168 | $3,112 |
| Ezetimibe | 57 | $2,414 |
| Nebivolol Hcl | 11 | $1,507 |
| Amlodipine Besylate | 173 | $1,246 |
| ClopidogrelClopidogrel Bisulfate | 64 | $1,162 |
| Amiodarone Hcl | 12 | $1,003 |
| Losartan Potassium | 98 | $748 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $17 | $137,923105 claims |
| Johnson & JohnsonXarelto | $316 | $42,30341 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in New Hyde Park
- Michael LevineNew Hyde Park$267K
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.